TNF inhibition as therapy for rheumatoid arthritis

Expert Opinion on Investigational Drugs

Volumn 11, Issue 7, 2002, Pages 947-953

  Wollheim, Frank A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arthritis; TNF inhibition

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOMALATE; BETA INTERFERON; CD40 LIGAND MONOCLONAL ANTIBODY; CHLOROQUINE; ENZYME INHIBITOR; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LEFLUNOMIDE; LENERCEPT; METHOTREXATE; NUCLEOSIDE ANALOG; ONERCEPT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SEMAPIMOD; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TRIPTERYGIUM WILFORDII EXTRACT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; FIBROBLAST; HUMAN; INFECTION; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RAT; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; HUMAN; INTERFERON-BETA; INTERLEUKINS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035986898     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.7.947     Document Type: Review

References (55)

1. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
2. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
3. Inhibition of tumor necrosis factor is protective against neurologic dysfunction after active immunization of Lewis rats with myelin basic protein
4. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
5. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis
6. Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: A possible mechanism of rheumatoid synovial hyperplasia and a clinical therapy for RA
7. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease
8. Infliximab induces apoptosis in monocytes from patients with chronic active Chrohn's diseaseby using a caspase-dependent pathway
9. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
10. Etanercept, infliximab and leflunomide in established rheumatoid arthritis. Clinical experience using a structured follow-up programme in southern Sweden
11. Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody
12. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis
13. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation
14. 3rd Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor Type I: A clinical update
15. Role of tumour necrosis factor alpha in experimental arthritis: Separate activity of interleukin 1beta in chronicity and cartilage destruction
16. Targeting interleukin-1 in the treatment of rheumatoid arthritis
17. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells
18. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis
19. An etiopathogenic role for the Type I IFN system in SLE
20. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: Comment on the case report by Jabaily and Thompson
21. Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: A therapeutic study using a macrophage-deactivating compound
22. A Phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma
23. Transcriptional down-regulation of tumor necrosis factor-alpha gene expression by a synthetic peptide homologous to retroviral envelope protein
24. Apomodulation as a novel therapeutic concept for the regulation of apoptosis in rheumatoid synoviocytes
25. Expression of Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE) inhibitory protein (FLIP) in human articular chondrocytes: Possible contribution to the resistance to human articular chondrocytes
26. Differential expression pattern of the antiapoptotic proteins, Bcl-2 and FLIP, in experimental arthritis
27. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: Evidence for a tumor necrosis factor alpha-mediated effect
28. NF-kappa B in rheumatoid arthritis: A pivotal regulator of inflammation, hyperplasia, and tissue destruction
29. Clinical course and remission rate in patients with early rheumatoid arthritis: Relationship to outcome after 5 years
30. Inhibition of mitogen-activated protein kinase signaling by chloroquine
31. Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells
32. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells
33. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis
34. Leflunomide: Mode of action in the treatment of rheumatoid arthritis
35. Leflunomide suppresses TNF-induced cellular responses: Effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis
36. Effects of gold on cytokine production in vitro; increase of monocyte dependent interleukin 10 production and decrease of interferon-gamma levels
37. Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway
38. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta
39. Sulphasalazine inhibits macrophage activation: Inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression
40. Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-kappaB activities
41. Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of 1 and 2 in human synovial fibroblasts
42. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
43. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
44. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis
45. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production
46. The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro
47. Immunotherapeutic and antitumour potential of thalidomide analogues
48. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF
49. Uncoupling of inflammatory and destructive mechanisms in arthritis
50. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis
51. Infliximab and methotrexate in the treatment of rheumatoid arthritis
52. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
53. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes
54. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation
55. Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IkappaB kinase